vs
Orthofix Medical Inc.（OFIX）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是PREFORMED LINE PRODUCTS CO的1.3倍（$219.9M vs $173.1M），PREFORMED LINE PRODUCTS CO净利率更高（4.9% vs -1.0%，领先5.9%），PREFORMED LINE PRODUCTS CO同比增速更快（3.6% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $11.8M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
OFIX vs PLPC — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$173.1M
营收增速更快
PLPC
高出1.6%
2.0%
净利率更高
PLPC
高出5.9%
-1.0%
自由现金流更多
OFIX
多$5.0M
$11.8M
两年增速更快
PLPC
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $173.1M |
| 净利润 | $-2.2M | $8.4M |
| 毛利率 | 71.1% | 29.8% |
| 营业利润率 | 0.2% | 6.8% |
| 净利率 | -1.0% | 4.9% |
| 营收同比 | 2.0% | 3.6% |
| 净利润同比 | 92.4% | -19.3% |
| 每股收益（稀释后） | $-0.05 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPLPC
| Q4 25 | $219.9M | $173.1M | ||
| Q3 25 | $205.6M | $178.1M | ||
| Q2 25 | $203.1M | $169.6M | ||
| Q1 25 | $193.6M | $148.5M | ||
| Q4 24 | $215.7M | $167.1M | ||
| Q3 24 | $196.6M | $147.0M | ||
| Q2 24 | $198.6M | $138.7M | ||
| Q1 24 | $188.6M | $140.9M |
净利润OFIXPLPC
| Q4 25 | $-2.2M | $8.4M | ||
| Q3 25 | $-22.8M | $2.6M | ||
| Q2 25 | $-14.1M | $12.7M | ||
| Q1 25 | $-53.1M | $11.5M | ||
| Q4 24 | $-29.1M | $10.5M | ||
| Q3 24 | $-27.4M | $7.7M | ||
| Q2 24 | $-33.4M | $9.4M | ||
| Q1 24 | $-36.0M | $9.6M |
毛利率OFIXPLPC
| Q4 25 | 71.1% | 29.8% | ||
| Q3 25 | 72.2% | 29.7% | ||
| Q2 25 | 68.7% | 32.7% | ||
| Q1 25 | 62.8% | 32.8% | ||
| Q4 24 | 69.0% | 33.3% | ||
| Q3 24 | 68.7% | 31.1% | ||
| Q2 24 | 67.8% | 31.9% | ||
| Q1 24 | 67.5% | 31.3% |
营业利润率OFIXPLPC
| Q4 25 | 0.2% | 6.8% | ||
| Q3 25 | -8.3% | 7.4% | ||
| Q2 25 | -7.9% | 10.1% | ||
| Q1 25 | -25.2% | 8.8% | ||
| Q4 24 | -5.3% | 10.5% | ||
| Q3 24 | -9.6% | 7.1% | ||
| Q2 24 | -12.5% | 8.1% | ||
| Q1 24 | -15.6% | 8.2% |
净利率OFIXPLPC
| Q4 25 | -1.0% | 4.9% | ||
| Q3 25 | -11.1% | 1.5% | ||
| Q2 25 | -6.9% | 7.5% | ||
| Q1 25 | -27.4% | 7.8% | ||
| Q4 24 | -13.5% | 6.3% | ||
| Q3 24 | -13.9% | 5.2% | ||
| Q2 24 | -16.8% | 6.8% | ||
| Q1 24 | -19.1% | 6.8% |
每股收益（稀释后）OFIXPLPC
| Q4 25 | $-0.05 | $1.72 | ||
| Q3 25 | $-0.57 | $0.53 | ||
| Q2 25 | $-0.36 | $2.56 | ||
| Q1 25 | $-1.35 | $2.33 | ||
| Q4 24 | $-0.76 | $2.13 | ||
| Q3 24 | $-0.71 | $1.54 | ||
| Q2 24 | $-0.88 | $1.89 | ||
| Q1 24 | $-0.95 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | — |
| 总债务越低越好 | — | $38.3M |
| 股东权益账面价值 | $450.0M | $475.5M |
| 总资产 | $850.6M | $653.6M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资OFIXPLPC
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — | ||
| Q1 24 | $27.0M | — |
总债务OFIXPLPC
| Q4 25 | — | $38.3M | ||
| Q3 25 | $157.2M | $36.0M | ||
| Q2 25 | $157.0M | $31.8M | ||
| Q1 25 | $156.9M | $29.1M | ||
| Q4 24 | $157.0M | $20.8M | ||
| Q3 24 | $118.5M | $27.2M | ||
| Q2 24 | $118.0M | $31.6M | ||
| Q1 24 | $118.2M | $55.0M |
股东权益OFIXPLPC
| Q4 25 | $450.0M | $475.5M | ||
| Q3 25 | $442.5M | $466.3M | ||
| Q2 25 | $458.3M | $460.7M | ||
| Q1 25 | $458.3M | $435.8M | ||
| Q4 24 | $503.1M | $422.3M | ||
| Q3 24 | $525.9M | $429.0M | ||
| Q2 24 | $546.0M | $416.2M | ||
| Q1 24 | $570.3M | $413.4M |
总资产OFIXPLPC
| Q4 25 | $850.6M | $653.6M | ||
| Q3 25 | $832.6M | $644.6M | ||
| Q2 25 | $837.2M | $631.5M | ||
| Q1 25 | $823.1M | $592.5M | ||
| Q4 24 | $893.3M | $573.9M | ||
| Q3 24 | $867.9M | $592.0M | ||
| Q2 24 | $882.0M | $572.6M | ||
| Q1 24 | $906.0M | $586.1M |
负债/权益比OFIXPLPC
| Q4 25 | — | 0.08× | ||
| Q3 25 | 0.36× | 0.08× | ||
| Q2 25 | 0.34× | 0.07× | ||
| Q1 25 | 0.34× | 0.07× | ||
| Q4 24 | 0.31× | 0.05× | ||
| Q3 24 | 0.23× | 0.06× | ||
| Q2 24 | 0.22× | 0.08× | ||
| Q1 24 | 0.21× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $11.8M |
| 自由现金流率自由现金流/营收 | 7.6% | 6.8% |
| 资本支出强度资本支出/营收 | 4.9% | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.60× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $33.3M |
8季度趋势，按日历期对齐
经营现金流OFIXPLPC
| Q4 25 | $27.7M | $21.9M | ||
| Q3 25 | $12.4M | $18.9M | ||
| Q2 25 | $11.6M | $26.9M | ||
| Q1 25 | $-18.4M | $5.7M | ||
| Q4 24 | $23.7M | $24.1M | ||
| Q3 24 | $11.7M | $9.4M | ||
| Q2 24 | $9.0M | $28.3M | ||
| Q1 24 | $-18.6M | $5.8M |
自由现金流OFIXPLPC
| Q4 25 | $16.8M | $11.8M | ||
| Q3 25 | $2.5M | $8.3M | ||
| Q2 25 | $4.5M | $18.6M | ||
| Q1 25 | $-25.1M | $-5.3M | ||
| Q4 24 | $15.2M | $20.6M | ||
| Q3 24 | $6.3M | $5.8M | ||
| Q2 24 | $-360.0K | $24.6M | ||
| Q1 24 | $-29.1M | $1.8M |
自由现金流率OFIXPLPC
| Q4 25 | 7.6% | 6.8% | ||
| Q3 25 | 1.2% | 4.7% | ||
| Q2 25 | 2.2% | 10.9% | ||
| Q1 25 | -13.0% | -3.6% | ||
| Q4 24 | 7.0% | 12.3% | ||
| Q3 24 | 3.2% | 3.9% | ||
| Q2 24 | -0.2% | 17.7% | ||
| Q1 24 | -15.4% | 1.3% |
资本支出强度OFIXPLPC
| Q4 25 | 4.9% | 5.9% | ||
| Q3 25 | 4.8% | 6.0% | ||
| Q2 25 | 3.5% | 4.9% | ||
| Q1 25 | 3.5% | 7.4% | ||
| Q4 24 | 4.0% | 2.1% | ||
| Q3 24 | 2.7% | 2.4% | ||
| Q2 24 | 4.7% | 2.7% | ||
| Q1 24 | 5.6% | 2.8% |
现金转化率OFIXPLPC
| Q4 25 | — | 2.60× | ||
| Q3 25 | — | 7.21× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 3.02× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PLPC
暂无分部数据
